Mini antibodies: biotech's next big thing?
Friday, September 12, 2008 - 03:42
in Biology & Nature
LONDON (Reuters) - GlaxoSmithKline Plc's head of biotech research is excited about a new generation of "slimline" antibody medicines that may be successors to current blockbusters such as Avastin and Rituxan.